共 282 条
[1]
Pollak MN(2004)Insulin-like growth factors and neoplasia Novartis Found Symp 262 84-98
[2]
Burtrum D(2003)A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo Cancer Res 63 8912-8921
[3]
Zhu Z(2005)In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors Clin Cancer Res 11 3065-3074
[4]
Lu D(2015)A phase I study of cixutumumab (IMC-A12) in combination with temsirolimus (CCI-779) in children with recurrent solid tumors: a Children’s Oncology Group phase 1 consortium report Clin Cancer Res 21 1558-1565
[5]
Anderson DM(2013)A phase I trial of the IGF-1R antibody cixutumumab in combination with temsirolimus in patients with metastatic breast cancer Breast Cancer Res Treat 139 145-153
[6]
Prewett M(2012)Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children’s Oncology Group J Clin Oncol 30 256-262
[7]
Pereira DS(2011)Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer Clin Cancer Res 17 6052-6060
[8]
Bassi R(2012)Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing’s sarcoma family tumors Clin Cancer Res 18 2625-2631
[9]
Abdullah R(2015)A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours Br J Cancer 112 24-31
[10]
Hooper AT(2014)A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma J Hepatol 60 319-324